GAO Report on ACT for ALS: What the Findings Mean for Access and Research
The Government Accountability Office (GAO) has released a new evaluation of how the Accelerating Access to Critical Therapies for ALS (ACT for ALS) Act is being implemented, and the takeaway is clear: early momentum is real, and the foundation for faster progress is being built. The GAO report on ACT for ALS reflects what families, clinicians, and advocates have been pushing for all along: urgency for people living with ALS today, paired with smart investments that strengthen the pathway to better treatments tomorrow.
Across the country, this law is helping eligible individuals pursue investigational therapies through expanded access, while also advancing the partnerships and data resources that make future breakthroughs more likely.
Why the GAO Report Matters Right Now
ALS does not move on a predictable timetable, and that reality shapes every policy conversation about treatment development. Traditional development pathways are important, but they can also be slow, and time is exactly what people with ALS don’t have. The ACT for ALS Act was created to confront that gap by supporting access to investigational therapies for eligible participants while preserving what we learn from those experiences so the field can advance faster.
The GAO’s February 4th, 2026 report underscores that this approach is already being put into practice. By looking at federal implementation and early outcomes, GAO helps Congress and the public understand whether the law is delivering on its intent. In this moment, that clarity matters because ACT for ALS has an authorization timeline, and decisions about sustaining momentum depend on what’s working and what must be strengthened.
How ACT for ALS Expands Access Without Losing the Learning
Expanded access can be a lifeline for some individuals who are not able to join a clinical trial, whether because of eligibility criteria, geography, or timing. The ACT for ALS framework supports expanded access programs while also encouraging learning from patient experience, so access and evidence-building move together rather than in competition.
What GAO Found: Funding, National Reach, and Research Infrastructure
One of the strongest indicators of early progress is that federal partners have put meaningful resources behind implementation. GAO reported that about $276 million was awarded from fiscal years 2022 through 2025 to implement ACT for ALS, supporting expanded access to investigational drugs, a rare neurodegenerative disease public–private partnership, and additional research and clinical development efforts.
The report also reflects tangible national reach through expanded access. Approximately 750 people with ALS are expected to receive investigational drugs through five National Institutes of Health (NIH) expanded access grants. Those grants are supported by 46 clinic sites prepared to enroll participants across 25 states, Washington, D.C., and Puerto Rico, alongside a remote option that can reach participants nationwide.
Beyond access, ACT for ALS investments are also strengthening the data backbone the ALS field needs. GAO noted that as of November 2025, 1,123 participants were enrolled in two Access for All in ALS (ALL ALS) Consortium natural history studies at 33 research sites across 25 states, Washington, D.C., and Puerto Rico. GAO also highlighted the ALS Knowledge Portal, publicly available since August 2025, which is centralizing high-quality ALS datasets for researchers, with 16 datasets listed as of September 2025.
Taken together, these findings show why ACT for ALS is an effort to increase access while building nationwide readiness for trials, research participation, and collaboration, so promising science can move more efficiently from labs to people.
How This Connects to Care, Clinics, and Support on the Ground
Policy reports can feel abstract until you connect them to what people experience day to day. At ALS New Mexico, we see the lived reality behind every statistic: the appointments, the equipment needs, the caregiver planning, and the urgent search for options. That’s why we keep our focus on supporting families now and helping shape systems that can deliver better care and treatments sooner.
For many people, the clinic is where research readiness and care coordination intersect. Multidisciplinary ALS clinics help individuals and families navigate complex needs, and they can also be an on-ramp to research participation when someone is eligible and interested. If you’re looking for guidance on where expert care can be found, our overview of ALS clinics and centers explains what specialized care teams do and how support can reduce barriers.
It also matters that ACT for ALS is helping sites become more prepared for enrollment and research coordination over time. When the system is better equipped, people have clearer pathways to participation, and clinics can sustain programs that strengthen both care and scientific progress.
What Reauthorization Means for Sustaining Momentum
GAO noted that building a first-of-its-kind program requires real coordination, and that funding and operational timelines can shape how quickly clinic sites move from award to enrollment. Those implementation realities are not unusual; they are part of launching something new at national scale. The good news, as reflected in the report and in the broader response from the ALS community, is that key components are underway—and impact can continue to grow.
That’s why reauthorization and stable, predictable funding matter. Without it, people could lose access to investigational therapies supported through the expanded access pathway, research sites could face interruptions that slow progress, and the field could lose momentum in building shared resources like natural history studies and data portals. The GAO report on ACT for ALS offers an evidence-based reason to keep building on what is working rather than resetting from scratch.
Take Action After the GAO Report on ACT for ALS
Progress happens when urgency is matched with sustained advocacy. If you want to help protect momentum behind expanded access, stronger research infrastructure, and better coordination across the ALS ecosystem, now is the time to get involved. You can add your voice by learning how to become an advocate, and if you have questions about advocacy opportunities, support services, or how to connect with resources, please contact ALS New Mexico. Together, we can keep pressure on the system to move faster, because for people living with ALS, time is everything.